ArticleBMC veterinary research2026
Expression of a recombinant lactoferrin N-terminal functional fragment in three expression systems and its efficacy against enterotoxigenic Escherichia coli K88 infection.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLactoferrin (LF) is a multifunctional iron-binding glycoprotein with antimicrobial and immunomodulatory properties. Its significant antimicrobial activity and negligible toxic side effects make it a potential therapeutic agent for antibacterial use. However, LF’s in vivo protective efficacy against Enterotoxigenic Escherichia coli K88 (ETEC K88), a major pathogen that causes diarrhea in newborn livestock, and its detailed immunoregulatory mechanisms remain incompletely understood. To address this knowledge gap, we constructed three engineered strains—KM71H-pPICZαA-rLF, EBY100-pYD1-rLF, and T7-B-pET-28a-rLF—to express the recombinant N-terminal functional fragments of LF, designated as rLF-N-PP, rLF-N-SC, and rLF-N-EC, respectively. They were successfully expressed, identified, and subjected to in vitro antibacterial activity analysis. Furthermore, mice infected with ETEC K88 were treated with rLF-N-PP, and clinical signs and histopathological changes in the intestines, liver, spleen, and kidneys were observed and recorded. Bacterial loads in the mesentery, cecum, liver, and spleen were measured, and levels of serum cytokines (TNF-α, IL-1β, IFN-γ, IL-10) and terminal ileal sIgA were quantified.
resultsThe results demonstrated successful expression of all three recombinant proteins. In vitro antibacterial assays showed that rLF-N-SC lacked antimicrobial activity, whereas rLF-N-PP exhibited significantly stronger antibacterial activity than rLF-N-EC. The inhibitory effect on Staphylococcus aureus was lower than that on E. coli.
conclusionsTreatment with rLF-N-PP improved clinical signs in mice infected with ETEC K88; markedly alleviated histopathological damage in the intestines, liver, spleen, and kidneys; reduced bacterial loads in the mesentery, cecum, liver, and spleen; decreased serum levels of pro-inflammatory cytokines (TNF-α, IL-1β, IFN-γ) and terminal ileal sIgA; and increased the level of the anti-inflammatory cytokine IL-10 compared to the K88 infection group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.